Ahead of final discussions currently taking place that will decide the fate of Clinical Trials Regulation in Europe, last week thirty-eight European medical, research and patient organisations sent a briefing document (PDF) on Clinical Trials Regulation to a number of prominent European contacts.
The briefing explains the importance of retaining proposed amendments which support clinical trial transparency in the draft regulation. A series of trilogue meetings relating to the draft legislation have been taking place since early November, with the last meeting expected to happen later this year and a decision expected early in the new year.
The 21-page briefing document (PDF) which was sent to permanent representatives, health attachés, secretaries, and a number of MEPs addresses each relevant amendment, citing both the proposed text along with an explanation of its importance. It also contains a two-page summary of clinical trials and why the reporting of clinical trial results is a public interest imperative.
Right now we’re fundraising for a video to spread awareness globally about why the information on what was found in clinical trials should be available. The video will capture the voices of patients, doctors and researchers, and we plan to have it subtitled into many languages to maximise its reach. We’re really close to reaching our target, so please give whatever you can afford and help us make a difference – let’s not lose this opportunity.